Gain Therapeutics, Inc.
GANX
$1.80
$0.063.45%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 8.34% | 3.83% | 2.08% | -8.68% | -26.59% |
| Total Depreciation and Amortization | -1.33% | 17.31% | 16.98% | 42.11% | 40.98% |
| Total Amortization of Deferred Charges | 2.17% | 5.62% | 10.34% | -3.09% | 22.67% |
| Total Other Non-Cash Items | -11.90% | -29.03% | 0.20% | 66.39% | 117.95% |
| Change in Net Operating Assets | -344.32% | -185.30% | -97.36% | -72.53% | -70.81% |
| Cash from Operations | -0.04% | -23.20% | -15.44% | -10.77% | -28.41% |
| Capital Expenditure | -46.41% | 12.96% | 72.66% | 96.48% | 87.14% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -51.16% | 13.05% | 88.84% | 188.84% | 169.86% |
| Cash from Investing | -51.31% | 13.14% | 91.33% | 187.95% | 169.19% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -2.13% | -3.07% | -4.88% | -44.71% | -12.94% |
| Issuance of Common Stock | 5.13% | 555.55% | 567.43% | 1,472.72% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.93% | 562.26% | 574.42% | 1,558.90% | 16,142.39% |
| Foreign Exchange rate Adjustments | -207.97% | 88.84% | -133.65% | -88.42% | 2,151.68% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -131.46% | 217.78% | 232.97% | 116.41% | 115.17% |